Total Wealth Planning & Management Inc. Trims Position in Johnson & Johnson $JNJ

Total Wealth Planning & Management Inc. decreased its position in shares of Johnson & Johnson (NYSE:JNJ) by 1.2% during the second quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 4,972 shares of the company’s stock after selling 61 shares during the quarter. Total Wealth Planning & Management Inc.’s holdings in Johnson & Johnson were worth $759,000 at the end of the most recent quarter.

A number of other institutional investors have also bought and sold shares of the business. Horizon Bancorp Inc. IN grew its holdings in Johnson & Johnson by 11.2% during the 2nd quarter. Horizon Bancorp Inc. IN now owns 636 shares of the company’s stock valued at $97,000 after buying an additional 64 shares in the last quarter. Global Strategic Investment Solutions LLC boosted its position in shares of Johnson & Johnson by 3.5% during the second quarter. Global Strategic Investment Solutions LLC now owns 1,925 shares of the company’s stock worth $294,000 after acquiring an additional 65 shares during the last quarter. JSF Financial LLC increased its holdings in Johnson & Johnson by 2.2% in the 2nd quarter. JSF Financial LLC now owns 2,993 shares of the company’s stock valued at $457,000 after acquiring an additional 65 shares during the last quarter. Elios Financial Group Inc. lifted its stake in Johnson & Johnson by 1.5% in the 1st quarter. Elios Financial Group Inc. now owns 4,496 shares of the company’s stock worth $746,000 after purchasing an additional 66 shares in the last quarter. Finally, Atlantic Family Wealth LLC boosted its holdings in shares of Johnson & Johnson by 4.4% during the 1st quarter. Atlantic Family Wealth LLC now owns 1,603 shares of the company’s stock valued at $266,000 after purchasing an additional 67 shares during the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insider Activity

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the business’s stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $190.66 on Friday. The firm has a market capitalization of $459.16 billion, a PE ratio of 20.39, a PEG ratio of 2.40 and a beta of 0.40. The stock’s fifty day moving average is $178.48 and its 200 day moving average is $163.77. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $192.10. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The company had revenue of $24.02 billion during the quarter. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s dividend payout ratio is 55.61%.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. The Goldman Sachs Group boosted their target price on Johnson & Johnson from $186.00 to $212.00 and gave the stock a “buy” rating in a research report on Thursday. Piper Sandler reaffirmed an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Wells Fargo & Company set a $212.00 target price on shares of Johnson & Johnson and gave the company an “overweight” rating in a report on Friday, October 3rd. Weiss Ratings raised shares of Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Wednesday. Finally, Sanford C. Bernstein lifted their price objective on shares of Johnson & Johnson from $172.00 to $193.00 and gave the stock a “market perform” rating in a research note on Monday, October 6th. Two analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $192.94.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.